Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies

Eiji Kikuchi, Nozomi Hayakawa, Keishiro Fukumoto, Keisuke Shigeta, Kazuhiro Matsumoto

Research output: Contribution to journalReview article

Abstract

Bacillus Calmette–Guérin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-invasive bladder cancer; however, one-third of patients treated with adequate bacillus Calmette–Guérin therapy do not achieve sufficient responses, and this is referred to as “bacillus Calmette–Guérin failure.” The term, bacillus Calmette–Guérin failure, is ambiguous and includes a very heterogeneous population of patients. By strictly focusing on patients who are unlikely to benefit from additional bacillus Calmette–Guérin therapy and who need to be treated with radical cystectomy, the new concept of “bacillus Calmette–Guérin unresponsive” was recently proposed, and might accelerate the development of novel therapeutic options for bacillus Calmette–Guérin-unresponsive disease. A promising therapeutic strategy for bacillus Calmette–Guérin-unresponsive disease is the blockade of the programmed cell death-1/programmed cell death-ligand 1 pathway, which is considered to be activated by bacillus Calmette–Guérin therapy. Several large clinical trials have been carried out to assess the potential of programmed cell death-1/programmed cell death-ligand 1 blockade in bacillus Calmette–Guérin-naïve high-risk non-muscle-invasive bladder cancer and bacillus Calmette–Guérin-unresponsive disease. Furthermore, clinical trials that are targeting bacillus Calmette–Guérin-unresponsive disease with other strategies, such as vaccines, gene therapy, and targeted and cytotoxic therapies, are ongoing. The findings of these trials are awaited in order to establish appropriate bladder-sparing approaches for patients with bacillus Calmette–Guérin-unresponsive disease.

Original languageEnglish
JournalInternational Journal of Urology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Urinary Bladder Neoplasms
Bacillus
Therapeutics
Cell Death
Clinical Trials
Active Immunotherapy
Cystectomy
Genetic Therapy
Urinary Bladder
Maintenance

Keywords

  • bacillus Calmette–Guérin
  • bladder cancer
  • cystectomy
  • non-muscle invasive
  • programmed cell death-1

ASJC Scopus subject areas

  • Urology

Cite this

Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer : Its definition and future therapeutic strategies. / Kikuchi, Eiji; Hayakawa, Nozomi; Fukumoto, Keishiro; Shigeta, Keisuke; Matsumoto, Kazuhiro.

In: International Journal of Urology, 01.01.2019.

Research output: Contribution to journalReview article

@article{fa9252e3e1b64ec4b7cb856fcddc8869,
title = "Bacillus Calmette–Gu{\'e}rin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies",
abstract = "Bacillus Calmette–Gu{\'e}rin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-invasive bladder cancer; however, one-third of patients treated with adequate bacillus Calmette–Gu{\'e}rin therapy do not achieve sufficient responses, and this is referred to as “bacillus Calmette–Gu{\'e}rin failure.” The term, bacillus Calmette–Gu{\'e}rin failure, is ambiguous and includes a very heterogeneous population of patients. By strictly focusing on patients who are unlikely to benefit from additional bacillus Calmette–Gu{\'e}rin therapy and who need to be treated with radical cystectomy, the new concept of “bacillus Calmette–Gu{\'e}rin unresponsive” was recently proposed, and might accelerate the development of novel therapeutic options for bacillus Calmette–Gu{\'e}rin-unresponsive disease. A promising therapeutic strategy for bacillus Calmette–Gu{\'e}rin-unresponsive disease is the blockade of the programmed cell death-1/programmed cell death-ligand 1 pathway, which is considered to be activated by bacillus Calmette–Gu{\'e}rin therapy. Several large clinical trials have been carried out to assess the potential of programmed cell death-1/programmed cell death-ligand 1 blockade in bacillus Calmette–Gu{\'e}rin-na{\"i}ve high-risk non-muscle-invasive bladder cancer and bacillus Calmette–Gu{\'e}rin-unresponsive disease. Furthermore, clinical trials that are targeting bacillus Calmette–Gu{\'e}rin-unresponsive disease with other strategies, such as vaccines, gene therapy, and targeted and cytotoxic therapies, are ongoing. The findings of these trials are awaited in order to establish appropriate bladder-sparing approaches for patients with bacillus Calmette–Gu{\'e}rin-unresponsive disease.",
keywords = "bacillus Calmette–Gu{\'e}rin, bladder cancer, cystectomy, non-muscle invasive, programmed cell death-1",
author = "Eiji Kikuchi and Nozomi Hayakawa and Keishiro Fukumoto and Keisuke Shigeta and Kazuhiro Matsumoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/iju.14153",
language = "English",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer

T2 - Its definition and future therapeutic strategies

AU - Kikuchi, Eiji

AU - Hayakawa, Nozomi

AU - Fukumoto, Keishiro

AU - Shigeta, Keisuke

AU - Matsumoto, Kazuhiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bacillus Calmette–Guérin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-invasive bladder cancer; however, one-third of patients treated with adequate bacillus Calmette–Guérin therapy do not achieve sufficient responses, and this is referred to as “bacillus Calmette–Guérin failure.” The term, bacillus Calmette–Guérin failure, is ambiguous and includes a very heterogeneous population of patients. By strictly focusing on patients who are unlikely to benefit from additional bacillus Calmette–Guérin therapy and who need to be treated with radical cystectomy, the new concept of “bacillus Calmette–Guérin unresponsive” was recently proposed, and might accelerate the development of novel therapeutic options for bacillus Calmette–Guérin-unresponsive disease. A promising therapeutic strategy for bacillus Calmette–Guérin-unresponsive disease is the blockade of the programmed cell death-1/programmed cell death-ligand 1 pathway, which is considered to be activated by bacillus Calmette–Guérin therapy. Several large clinical trials have been carried out to assess the potential of programmed cell death-1/programmed cell death-ligand 1 blockade in bacillus Calmette–Guérin-naïve high-risk non-muscle-invasive bladder cancer and bacillus Calmette–Guérin-unresponsive disease. Furthermore, clinical trials that are targeting bacillus Calmette–Guérin-unresponsive disease with other strategies, such as vaccines, gene therapy, and targeted and cytotoxic therapies, are ongoing. The findings of these trials are awaited in order to establish appropriate bladder-sparing approaches for patients with bacillus Calmette–Guérin-unresponsive disease.

AB - Bacillus Calmette–Guérin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-invasive bladder cancer; however, one-third of patients treated with adequate bacillus Calmette–Guérin therapy do not achieve sufficient responses, and this is referred to as “bacillus Calmette–Guérin failure.” The term, bacillus Calmette–Guérin failure, is ambiguous and includes a very heterogeneous population of patients. By strictly focusing on patients who are unlikely to benefit from additional bacillus Calmette–Guérin therapy and who need to be treated with radical cystectomy, the new concept of “bacillus Calmette–Guérin unresponsive” was recently proposed, and might accelerate the development of novel therapeutic options for bacillus Calmette–Guérin-unresponsive disease. A promising therapeutic strategy for bacillus Calmette–Guérin-unresponsive disease is the blockade of the programmed cell death-1/programmed cell death-ligand 1 pathway, which is considered to be activated by bacillus Calmette–Guérin therapy. Several large clinical trials have been carried out to assess the potential of programmed cell death-1/programmed cell death-ligand 1 blockade in bacillus Calmette–Guérin-naïve high-risk non-muscle-invasive bladder cancer and bacillus Calmette–Guérin-unresponsive disease. Furthermore, clinical trials that are targeting bacillus Calmette–Guérin-unresponsive disease with other strategies, such as vaccines, gene therapy, and targeted and cytotoxic therapies, are ongoing. The findings of these trials are awaited in order to establish appropriate bladder-sparing approaches for patients with bacillus Calmette–Guérin-unresponsive disease.

KW - bacillus Calmette–Guérin

KW - bladder cancer

KW - cystectomy

KW - non-muscle invasive

KW - programmed cell death-1

UR - http://www.scopus.com/inward/record.url?scp=85076323049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076323049&partnerID=8YFLogxK

U2 - 10.1111/iju.14153

DO - 10.1111/iju.14153

M3 - Review article

C2 - 31793703

AN - SCOPUS:85076323049

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

ER -